BLASUBCUTANEOUSINJECTABLE1 Generic Approved
Approved
Mar 2025
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
3/8 — Basic
TYENNE (tocilizumab-aazg) by Fresenius Kabi is interleukin 6 receptor antagonists [moa]. Approved for rheumatoid arthritis, giant cell arteritis, takayasu arteritis and 7 more indications. First approved in 2025.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TYENNE is a tocilizumab-aazg subcutaneous injection, an interleukin-6 receptor antagonist monoclonal antibody approved by the FDA on March 14, 2025. It treats a broad spectrum of inflammatory and autoimmune conditions including rheumatoid arthritis, giant cell arteritis, vasculitis, juvenile idiopathic arthritis, and COVID-19 pneumonia. The drug works by blocking IL-6 receptor signaling, suppressing systemic inflammation across multiple disease pathways.
Growth
Early-stage growth product with moderate competitive pressure (30/100) offers expansion opportunities for brand and medical teams building market presence.
Mechanism of Action
Interleukin 6 Receptor Antagonists
Pharmacologic Class:
Interleukin-6 Receptor Antagonist
Indications (10)
Worked on TYENNE at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.